LOS ALTOS, Calif.--(BUSINESS WIRE)--
CardioLogical Solutions, an emerging cardiovascular device
company, announced today that it has initiated operations. CardioLogical
Solutions represents the merger of two independent companies—Emboline
and VasoStitch. Financial details of the merger were not
disclosed. David W. J. Smith, previously president and CEO of
VasoStitch, is chief executive officer of the new business.
The large-hole access and closure technologies of VasoStitch and the
aortic embolic protection technologies of Emboline form the initial core
of a family of accessory devices offered by CardioLogical Solutions to
address the clinical needs of emerging interventional cardiology
procedures. Added to these is a novel approach to preventing contrast
nephropathy during cardiovascular procedures. The technologies of
CardioLogical Solutions are derived from intellectual property invented
by serial entrepreneur Amir Belson, M.D., founder of NeoGuide
Systems, Vascular Pathways, Zipline Medical, Thermocure
and Radguard Medical.
“Recent developments in interventional cardiology have created
compelling opportunities for new types of procedural accessory devices,”
said Dr. Belson. “Specifically, the recent emergence of transcatheter
aortic valve replacement (TAVR) therapies has created a critical need
for non-surgical, large-hole (>12 Fr) access and closure technologies,
aortic embolic protection devices for prevention of stroke and other
ischemic complications, and prevention of contrast nephropathy. The
combined potential of these markets where there exists now a
strong clinical need is estimated at $2 to 3 billion annually, and this
is the immediate focus of CardioLogical Solutions.”
“Merging these companies will both create cost-efficiencies and enhance
the value of the combined enterprise,” added David W. J. Smith,
CardioLogical Solutions' CEO. “The broad portfolio of CardioLogical
Solutions represents the most comprehensive range of accessory products
for the TAVR community. Our technologies address the three biggest
clinical needs in TAVR, with superior technologies and a broad
intellectual property portfolio.”
CardioLogical Solutions is currently in the advanced stages of raising a
Series B preferred round to achieve CE mark for the initial Emboline and
VasoStitch products, and proof-of-concept for its contrast nephropathy
technology. First commercial sales are estimated in the ninth calendar
quarter following close of funding, beginning with the European launch
of the first VasoStitch product, followed by the European launch of the
first Emboline device approximately six months later.
About CardioLogical Solutions
Privately held CardioLogical Solutions is an emerging medical technology
company focused on developing novel accessory devices for interventional
cardiology procedures. For example, the recent emergence of
transcatheter aortic valve replacement (TAVR) therapies has created a
critical need for non-surgical, large-hole (>12 Fr) access and closure
technologies, aortic embolic protection devices for prevention of stroke
and other ischemic complications, and prevention of contrast
nephropathy. The combined potential for these three markets where there
exists now a strong clinical need is estimated at $2 to 3
billion. CardioLogical Solutions was founded by serial entrepreneur Amir
Belson, M.D.
NOTICE: CardioLogical Solutions' products are not available for sale in
the United States.
